Evoke Pharma Ownership
| EVOK Stock | USD 3.21 0.28 8.02% |
Shares in Circulation | First Issued 2012-03-31 | Previous Quarter 1.4 M | Current Value 1.4 M | Avarage Shares Outstanding 1.6 M | Quarterly Volatility 1.2 M |
Evoke |
Evoke Stock Ownership Analysis
About 15.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.74. Some equities with similar Price to Book (P/B) outperform the market in the long run. Evoke Pharma recorded a loss per share of 2.81. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 1st of August 2024. Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California. Evoke Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. To learn more about Evoke Pharma call David RPh at 858 345 1494 or check out https://www.evokepharma.com.Besides selling stocks to institutional investors, Evoke Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Evoke Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Evoke Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Evoke Pharma Quarterly Liabilities And Stockholders Equity |
|
Evoke Pharma Insider Trades History
About 5.0% of Evoke Pharma are currently held by insiders. Unlike Evoke Pharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Evoke Pharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Evoke Pharma's insider trades
Evoke Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Evoke Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evoke Pharma backward and forwards among themselves. Evoke Pharma's institutional investor refers to the entity that pools money to purchase Evoke Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Investments N A | 2024-12-31 | 0.0 | Citigroup Inc | 2024-12-31 | 0.0 | Nantahala Capital Management, Llc | 2024-12-31 | 148.2 K | Bleichroeder Lp | 2024-12-31 | 68.8 K | Ubs Group Ag | 2024-12-31 | 1.3 K | Blackrock Inc | 2024-12-31 | 122 | Sbi Securities Co Ltd | 2024-12-31 | 75.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 31.0 | Goss Wealth Management Llc | 2024-12-31 | 17.0 | Bank Of America Corp | 2024-12-31 | 9.0 | Aigh Capital Management, Llc | 2024-12-31 | 0.0 |
Evoke Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evoke Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evoke Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evoke Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nantahala Capital Management, Llc a day ago Insider Trading | ||
Nantahala Capital Management, Llc 2 days ago Insider Trading | ||
Nantahala Capital Management, Llc six days ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over two weeks ago Insider Trading | ||
Nantahala Capital Management, Llc over two weeks ago Insider Trading | ||
Nantahala Capital Management, Llc over two weeks ago Insider Trading |
Evoke Pharma Outstanding Bonds
Evoke Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Evoke Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Evoke bonds can be classified according to their maturity, which is the date when Evoke Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| EVERSOURCE ENERGY 33 Corp BondUS30040WAE84 | View | |
| EVERSOURCE ENERGY 425 Corp BondUS30040WAF59 | View | |
| EVERSOURCE ENERGY 335 Corp BondUS30040WAB46 | View | |
| ES 14 15 AUG 26 Corp BondUS30040WAN83 | View | |
| ES 255 15 MAR 31 Corp BondUS30040WAL28 | View | |
| US30040WAK45 Corp BondUS30040WAK45 | View | |
| US30040WAJ71 Corp BondUS30040WAJ71 | View | |
| Eversource Energy 345 Corp BondUS30040WAH16 | View |
Evoke Pharma Corporate Filings
8K | 13th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of February 2025 Other Reports | ViewVerify | |
| 22nd of November 2024 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.81) | Revenue Per Share | Quarterly Revenue Growth 0.974 | Return On Assets | Return On Equity |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.